Instead, we hypothesized that tumor-infiltrating Treg may have a higher immunosuppressive capacity compared to Treg from unaffected colon and peripheral blood, as an effect of their higher frequencies of CD39+ Treg in the tumors. This evidence concerns the gene ENTPD1 and neoplasm.